We are live on ! Find out more
SM

Sabby Management Portfolio holdings

AUM $111M
1-Year Est. Return 74.4%
This Fund
S&P 500
This Quarter Est. Return
-6.02%
1 Year Est. Return
-74.4%
3 Year Est. Return
-95.55%
5 Year Est. Return
-99.44%
10 Year Est. Return
-99.5%
AUM
$1.53B
AUM Growth
-$325M
Cap. Flow
+$93M
Cap. Flow %
6.09%
Top 10 Hldgs %
65.86%
Holding
300
New
43
Increased
68
Reduced
83
Closed
84

Top Buys

Rank Stock Value
1
BMY icon
Bristol-Myers Squibb
BMY
+$95.6M
2
TSRO
TESARO, Inc.
TSRO
+$7.45M
3
SGEN
Seagen Inc. Common Stock
SGEN
+$5.41M
4
MBOT icon
Microbot Medical
MBOT
+$4.73M
5
UTHR icon
United Therapeutics
UTHR
+$4.46M

Top Sells

Rank Stock Value
1
AMGN icon
Amgen
AMGN
+$6.09M
2
IONS icon
Ionis Pharmaceuticals
IONS
+$5.39M
3
MTFB
Motif Bio plc ADRs
MTFB
+$4.6M
4
OTIC
Otonomy, Inc.
OTIC
+$3.19M
5
PALI icon
Palisade Bio
PALI
+$2.63M

Sector Composition

Rank Sector Weight
1 Miscellaneous 86.02%
2 Healthcare 13.32%
3 Materials 0.27%
4 Technology 0.24%
5 Financials 0.11%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
PTCT icon
251
PUT
PTC Therapeutics
PTCT
$5.55B
– –
-649
Closed -$639K
RARE icon
252
PUT
Ultragenyx Pharmaceutical
RARE
$1.34B
– –
-394
Closed -$2.67M
RDHL
253
Redhill Biopharma
RDHL
$3.73M
– –
-108
Closed -$1.04M
SAGE
254
DELISTED
Sage Therapeutics
SAGE
– –
-3,379
Closed -$244K
SINT icon
255
SiNtx Technologies
SINT
$12M
– –
0
– -$751K
SPY icon
256
CALL
State Street SPDR S&P 500 ETF Trust
SPY
$803B
– –
-5,999
Closed -$141M
SYBX
257
DELISTED
Synlogic
SYBX
– –
-105
Closed -$24K
TENX icon
258
Tenax Therapeutics
TENX
$69.6M
– –
-36
Closed -$300K
TGTX icon
259
PUT
TG Therapeutics
TGTX
$8.27B
– –
-488
Closed -$569K
TXMD icon
260
CALL
TherapeuticsMD
TXMD
$25M
– –
-5
Closed -$180K
VCEL icon
261
Vericel Corp
VCEL
$2.03B
– –
-14,694
Closed -$41K
CSCI
262
PUT
DELISTED
COSCIENS Biopharma Inc. Common Stock
CSCI
– –
-2
Closed -$50K
CMRX
263
DELISTED
Chimerix, Inc.
CMRX
– –
-21,200
Closed -$135K
ITCI
264
CALL
DELISTED
Intra-Cellular Therapies Inc.
ITCI
– –
-158
Closed -$257K
LUMO
265
CALL
DELISTED
Lumos Pharma, Inc. Common Stock
LUMO
– –
-268
Closed -$5.82M
NURO
266
DELISTED
NeuroMetrix, Inc. Common Stock
NURO
– –
-472
Closed -$187K
PRTK
267
CALL
DELISTED
Paratek Pharmaceuticals, Inc.
PRTK
– –
-1,141
Closed -$2.2M
PRTK
268
PUT
DELISTED
Paratek Pharmaceuticals, Inc.
PRTK
– –
-1,025
Closed -$1.97M
ACOR
269
CALL
DELISTED
Acorda Therapeutics
ACOR
– –
-1
Closed -$313K
ACOR
270
DELISTED
Acorda Therapeutics
ACOR
– –
-638
Closed -$1.61M
ACOR
271
PUT
DELISTED
Acorda Therapeutics
ACOR
– –
-58
Closed -$14.7M
BLCM
272
DELISTED
Bellicum Pharmaceuticals, Inc.
BLCM
– –
-7,250
Closed -$895K
SIOX
273
DELISTED
Sio Gene Therapies Inc. Common Stock
SIOX
– –
-2,089
Closed -$366K
RDUS
274
DELISTED
Radius Health, Inc.
RDUS
– –
-25,828
Closed -$998K
RDUS
275
PUT
DELISTED
Radius Health, Inc.
RDUS
– –
-454
Closed -$1.75M
8 9 10
11
12

Similar funds

IWA
Independent Wealth Advisors Cary, North Carolina $111M AUM
BFA
Ballast Financial Advisors West Chester, Pennsylvania $110M AUM
WPWM
Western Pacific Wealth Management Lake Forest, Illinois $111M AUM 26.64% 1-Year Est. Return
BCM
Beryl Capital Management Redondo Beach, California $111M AUM 205.39% 1-Year Est. Return
ZS
Zenith Solutions Philadelphia, Pennsylvania $110M AUM
KC
Karras Company Roy, Utah $110M AUM
FI
FinArc Investments Norwood, Massachusetts $110M AUM
CIM
Catalyst Investment Management Windham, New Hampshire $110M AUM

Sabby Management's Q2 2017 Portfolio in Review

As of Q2 2017, Sabby Management held 300 positions worth $1.53B, down 18% from $1.85B the previous quarter. Its ten largest holdings account for 66% of the portfolio.

Sabby Management deployed $93M of net new capital in Q2 2017, opening 43 new positions and adding to 68 existing holdings. Its largest new stake was TESARO, Inc.: 51,426 shares worth $7.19M.

By sector, the portfolio is most concentrated in Miscellaneous at 86% of assets, down from 93% a quarter earlier, followed by Healthcare and Materials.

On the sell side, the largest reduction was Otonomy, Inc., an estimated $3.19M trimmed.

  • Sabby Management's largest Q2 2017 buy was TESARO, Inc.: 51,426 shares worth $7.19M.
  • Sabby Management added most to Bristol-Myers Squibb in Q2 2017, an estimated $95.6M increase.
  • Sabby Management's biggest Q2 2017 reduction was Otonomy, Inc., cutting an estimated $3.19M.
  • Sabby Management fully exited Amgen in Q2 2017, selling an estimated $6.09M.
  • Sabby Management's ten largest holdings make up 66% of its $1.53B portfolio in Q2 2017.
  • Sabby Management opened 43 new positions and closed 84 in Q2 2017.
  • Sabby Management's portfolio value fell 18% quarter-over-quarter to $1.53B.

Based on Sabby Management's 13F filing for Q2 2017, filed 14 Aug 2017.